To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
take tenofovir disoproxil fumarate 300mg/d
Guohua Zhao
Hangzhou, Zhejiang, China
RECRUITINGUPDRS III(Unified Parkinson's Disease Rating Scale part 3)
score:0-132,higher scores mean a worse outcome
Time frame: 1 month、3 month
Non-Motor Symptom Scale(NMSS)
score:0-360,higher scores mean a worse outcome
Time frame: 1 month、3 month
creatinine(μmoI/L)
blood biochemistry test,normal\<97μmoI/L
Time frame: 1 month、3 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.